11c-ps13

Phase 1

NNational Institute of Mental Health (NIMH)

11c-ps13 is one of 18 therapeutic programs targeting Parkinson's Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Parkinson's DiseaseRecruiting

Long COVIDRecruiting

Parkinson's DiseasePhase 1

Recruiting

Long COVIDPhase 1

Recruiting

Competition

Competitive Landscape

17 competitors in Parkinson's Disease

#DrugCompanyPhaseTrials

Ingrezza

Neurocrine Biosciences

Approved

—2

Nourianz

Kyowa Kirin Co., Ltd.

Phase 3

12 3

Requip Xl

GGlaxo Dba Glaxosmithkline

Phase 3

7 4

Comtan

Orion Corporation, Orion Pharma

Phase 2

3 5

Leqembi

Kisunla

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 2

1 8

Prasinezumab

Roche

Phase 3

3 9

Ongentys

AAmneal Pharmaceuticals, LLC

Phase 1

3 10

ND0612

NNeuroDerm Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Long COVID

NCT06920628

Q4 2030

Phase 1Recruiting

Parkinson's Disease

NCT04396873

Clinical

Trials by Indication[1]

Long COVID1 trial

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Recruiting·NNational Institute of Mental Health (NIMH)·Phase 1·NCT06920628·60 enrolled

Parkinson's Disease1 trial

Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Recruiting·NNational Institute of Mental Health (NIMH)·Phase 1·NCT04396873·184 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for 11c-ps13. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 11c-ps13. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Institute of Mental Health (NIMH) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNational Institute of Mental Health (NIMH)

11c-ps13

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q4 2030

Trials by Indication[1]

Long COVID1 trial

Parkinson's Disease1 trial

References

Drug Info

Quick Facts

Related News